Literature DB >> 9829488

Clostridium difficile colitis associated with chronic renal failure.

R J Cunney1, C Magee, E McNamara, E G Smyth, J Walshe.   

Abstract

BACKGROUND: Clostridium difficile-associated diarrhoea (CDAD) is a potentially life-threatening illness which has been shown to be more common and more severe in patients with chronic renal failure (CRF) than in other groups. A review of CDAD in our nephrology unit was carried out.
METHODS: A review of microbiology and histology records identified 32 cases of CDAD in the nephrology unit over a 24-month period. Patient notes were reviewed to identify risk factors, clinical features and outcome. Available isolates of C. difficile underwent 16S ribosomal RNA typing.
RESULTS: The incidence of CDAD in the nephrology unit was 10.7 per 1000 admissions, compared to 2.7 per 1000 in other areas of the hospital (P<0.0001). CDAD was considered the sole or principal cause of death in six (19%) and was considered a contributing factor in a further seven (22%). Mortality was significantly higher among patients with established CRF (P=0.04). Seven cases occurred as a cluster, over a 1-month period. Isolates from this cluster, along with comparative strains from other areas of the hospital, were found to be PCR type 1. Diarrhoea occurred in 28 (89%) of cases, pyrexia in 17 (53%) and ileus or abdominal pain in 14 (44%). Six patients responded to discontinuation of antibiotics alone and 22 required metronidazole and/or vancomycin. Three patients had colectomy and one caecostomy because of toxic megacolon. Four patients died before specific therapy could be given and in two of these cases the diagnosis was made at autopsy. Twenty-six patients had a record of recent antibiotic therapy. Of these, 15 had at least one agent considered to be inappropriate (excessively broad spectrum agent in 11, excessive duration of therapy in four). Nine patients had only received antibiotics prior to admission.
CONCLUSIONS: CDAD carries a high mortality in nephrology patients, especially those with established CRF. The diagnosis may be missed if a careful antibiotic history is not taken, including agents received prior to admission. Rational antibiotic prescribing and adherence to infection control measures are vital to reduce the incidence of this serious condition.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9829488     DOI: 10.1093/ndt/13.11.2842

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  27 in total

1.  Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models.

Authors:  Jennifer Steele; Kevin Chen; Xingmin Sun; Yongrong Zhang; Haiying Wang; Saul Tzipori; Hanping Feng
Journal:  J Infect Dis       Date:  2011-12-05       Impact factor: 5.226

2.  An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivo.

Authors:  Scott M Baliban; Amanda Michael; Berje Shammassian; Shikata Mudakha; Amir S Khan; Simon Cocklin; Isaac Zentner; Brian P Latimer; Laurent Bouillaut; Meredith Hunter; Preston Marx; Niranjan Y Sardesai; Seth L Welles; Jeffrey M Jacobson; David B Weiner; Michele A Kutzler
Journal:  Infect Immun       Date:  2014-07-14       Impact factor: 3.441

3.  Mouse relapse model of Clostridium difficile infection.

Authors:  Xingmin Sun; Haiying Wang; Yongrong Zhang; Kevin Chen; Barbara Davis; Hanping Feng
Journal:  Infect Immun       Date:  2011-05-16       Impact factor: 3.441

Review 4.  Clostridium difficile infection: molecular pathogenesis and novel therapeutics.

Authors:  Ardeshir Rineh; Michael J Kelso; Fatma Vatansever; George P Tegos; Michael R Hamblin
Journal:  Expert Rev Anti Infect Ther       Date:  2014-01       Impact factor: 5.091

Review 5.  Chronic kidney disease and end-stage renal disease are risk factors for poor outcomes of Clostridium difficile infection: a systematic review and meta-analysis.

Authors:  C Thongprayoon; W Cheungpasitporn; P Phatharacharukul; P J Edmonds; Q Kaewpoowat; P Mahaparn; J Bruminhent; S B Erickson
Journal:  Int J Clin Pract       Date:  2015-07-05       Impact factor: 2.503

6.  A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection.

Authors:  Haiying Wang; Xingmin Sun; Yongrong Zhang; Shan Li; Kevin Chen; Lianfa Shi; Weijia Nie; Raj Kumar; Saul Tzipori; Jufang Wang; Tor Savidge; Hanping Feng
Journal:  Infect Immun       Date:  2012-05-21       Impact factor: 3.441

7.  Identification of Clostridium difficile toxin B cardiotoxicity using a zebrafish embryo model of intoxication.

Authors:  Elaine E Hamm; Daniel E Voth; Jimmy D Ballard
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-11       Impact factor: 11.205

8.  Vancomycin-resistant peritonitis associated with peritoneal dialysis: a cause for concern.

Authors:  A O'Riordan; K A Abraham; J Kee Ho; J J Walshe
Journal:  Ir J Med Sci       Date:  2002 Jan-Mar       Impact factor: 1.568

9.  Univariate and multivariate analysis of risk factors for severe Clostridium difficile-associated diarrhoea: importance of co-morbidity and serum C-reactive protein.

Authors:  Christian Hardt; Thomas Berns; Wolfgang Treder; Franz-Ludwig Dumoulin
Journal:  World J Gastroenterol       Date:  2008-07-21       Impact factor: 5.742

Review 10.  Variations in virulence and molecular biology among emerging strains of Clostridium difficile.

Authors:  Jonathan J Hunt; Jimmy D Ballard
Journal:  Microbiol Mol Biol Rev       Date:  2013-12       Impact factor: 11.056

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.